Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. - Wikidata - awgldk - TriplyDB

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

http://www.wikidata.org/entity/Q36296752

about

Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Uptake carriers and oncology drug safety.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.Hepatic uptake transporters and docetaxel disposition in mice-letter Editors' pick 2012.Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

P2860

Q26829894-0EFAD0B8-1AB9-4FFE-8606-15DAD2D2546A Q28239708-5D0C8EC5-D639-4B68-A9BA-E6296C1A2C3B Q28943314-CD939532-3E4D-45B5-BA2B-4D85EFD1D08B Q30584978-DE545FEE-80AE-410C-B8CE-4CCF258B36E3 Q35375045-EEA0B64D-5E22-402E-ABA3-C4E1E2B67523 Q36072504-CAAF79A4-8C2F-4DF8-8DC5-91D8F8131721 Q36072512-0832A426-FE64-4F16-9772-53CA93E47A0E Q36616448-AE28C3D8-1E1E-4E58-8144-61AB9FB8DF71 Q36698681-9A37080E-FCD6-4E39-8D8D-52C48C5948AC Q36824621-94E16F77-89A8-49E1-A9BA-4B869BE02EF5 Q36981855-48ED2AC9-D0CE-472A-8150-4E7BCCA2B091 Q37093336-CD9E8D9F-F550-4A13-A492-20F68813182F Q37279044-C0E11C29-D0A8-4F45-9D25-F11233419897 Q37394474-DC0DE47C-D337-4058-B48D-DCBA482B4BB7 Q37439697-6C4BC3E0-6818-4BB6-9E3B-8119C614CF57 Q37594395-0044E97B-CF1E-4900-BDE1-BF9212361AD8 Q37663396-87D80AB2-14DA-4606-BBED-44533D3C291F Q38336723-D0C1CB67-667E-46FB-ADA1-FD355FEC5592 Q38737388-5FD1A9D3-C443-4405-8FA1-AA6853E98318 Q38888345-828CB709-F570-4754-85AE-274DE926A6C2 Q38933314-E7774F33-504A-4C82-80B8-10A344DE835C Q38937228-C7E1DD72-1802-4DB2-934D-E0D23A0B444B Q39001980-61F5A93F-9253-4027-8934-61AAF39F3DCF Q39317847-D2B4FAAC-2A68-407E-A233-8446BDA3A529 Q40566915-A55297D5-6B9F-412C-9E55-9FF143B9F302 Q41658065-2B0CC64F-1C4E-4704-8020-EE016046623C Q42780486-96841479-1B94-49E7-9C52-28A76344A359 Q42976095-4541816C-32C3-4C4B-BB6A-A474175B30EB Q47281772-41DCA30D-67C4-4CD4-B13E-516F4A976C29 Q47558946-67B46A66-AB2B-45AF-B783-5A4E91DACEBC Q53065608-C5A64BD4-07BE-459E-8F31-E5F26CCAE66A

P2860

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

http://www.wikidata.org/entity/Q36296752

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@ast

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@en

type

label

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@ast

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@en

prefLabel

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@ast

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@en

P1433

Q36296752-64B6C72B-94D0-4457-AB9B-9E51CEBC405D

P1476

Q36296752-537BCED8-0263-47A2-851A-714800C21F2E

P2093

Q36296752-02E7E30F-B8E1-4395-82FC-14B296EE77C4

Q36296752-114F2849-0FCB-4FB3-ACAF-F4E947E5544B

Q36296752-332932FA-7734-4A97-8D24-1427C223FC13

Q36296752-44BAA05A-55F5-494D-8FC2-3F287AB28B15

Q36296752-4DA93CC5-9881-4BDF-B144-1F70C474EC40

Q36296752-5B21589D-D0B4-40E5-A2A0-2CFED64E5FE0

Q36296752-5F4C97EB-F232-40B2-A171-221BB3733BA0

Q36296752-65C1449D-7359-429C-8584-D6FE22A5026D

Q36296752-71134389-2FC4-4589-8EFE-EF624DE3B56C

Q36296752-73FC5D43-124C-4C18-AC25-197DB677D476

P2860

Q36296752-0718D9D0-39B0-43D7-B770-DCEC950CDD99

Q36296752-1252B217-8B91-4BD0-A03D-C504404B036B

Q36296752-1B9AF182-865B-43F2-8FB6-7979B26F52E7

Q36296752-1C6AD754-F54D-4FEB-8C9D-5DF0434832C1

Q36296752-1DF1C87F-A82C-4D22-B640-1B96CFE8E9BD

Q36296752-1E5CEE08-0A03-41DA-9371-C5FC31B9F9CD

Q36296752-28962FC0-9BF8-4703-9B09-93D007C3D304

Q36296752-438EB6AC-37C4-4944-9A8D-A17626B4A356

Q36296752-5161417B-1AC7-4043-ADCB-22FB907B3779

Q36296752-51C40657-34B8-49AA-AE6A-A0709E89B5EB

P304

Q36296752-4CFA77B6-46AC-43FB-976A-A0D0D984573C

P31

Q36296752-46F47F71-C42C-4785-9746-ED5A982853E7

P356

Q36296752-DFB3D799-3A86-4A93-AE8D-ADE69BFDBA19

P407

Q36296752-2892F02B-DC3F-45C4-B75C-D761B0889D4F

P433

Q36296752-9C0C3E11-B09A-47AB-AE11-0358A0BE4BCF

P478

Q36296752-ADB438ED-8028-47B6-A362-333CC113C44C

P50

Q36296752-1502A20F-9F85-4D93-A85A-DC401686BEE1

P577

Q36296752-317A7A91-244D-47EF-896F-71BBC7454931

P698

Q36296752-EA4A15F4-ECC5-4CE4-AE13-33650D2B1119

P932

Q36296752-5C0578BD-120A-4434-B15A-8CCC9535FFB3

P356

1078-0432.CCR-12-0761

P1433

Clinical Cancer Research

P1476

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

@en

P2093

Aisha L Walker

http://www.w3.org/2001/XMLSchema#string

Alice A Gibson

http://www.w3.org/2001/XMLSchema#string

Amanda Obaidat

http://www.w3.org/2001/XMLSchema#string

Anne-Joy M de Graan

http://www.w3.org/2001/XMLSchema#string

Bruno Hagenbuch

http://www.w3.org/2001/XMLSchema#string

Cynthia S Lancaster

http://www.w3.org/2001/XMLSchema#string

Gitte H Bruun

http://www.w3.org/2001/XMLSchema#string

Guoqing Du

http://www.w3.org/2001/XMLSchema#string

Laure Elens

http://www.w3.org/2001/XMLSchema#string

Lena E Friberg

http://www.w3.org/2001/XMLSchema#string

P2860

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

Membrane transporters in drug development

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.

Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.

Impact of OATP transporters on pharmacokinetics.

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition

Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.

P304

4433-4440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0761

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Alex Sparreboom

P577

2012-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22711709

http://www.w3.org/2001/XMLSchema#string

P932

3464009

http://www.w3.org/2001/XMLSchema#string